📜 Reclassifying Medical Marijuana Is a Milestone, but Advocates Say It Falls Short

An opinion piece from News from the States argues that the federal government’s decision to reclassify medical marijuana is a long‑overdue acknowledgment of its legitimate medical use, aligning federal policy with decades of state legalization and scientific consensus. However, the author contends the move is insufficient on its own, as it does not fully resolve conflicts between state and federal law or expand access for patients in states without medical cannabis programs. While rescheduling may ease research barriers and validate existing programs, broader reforms, such as comprehensive federal legalization or harmonized regulation, are still needed to ensure consistent patient access and policy coherence nationwide. (News From The States)

🌿 High‑Potency Cannabis Drives State Debates Over Psychosis and Addiction Risks

An emerging wave of research linking high‑THC cannabis to increased risks of addiction, psychosis and other mental health issues is fueling renewed policy debates across states over how strong legal cannabis products should be. While modern products often contain 15–20% THC or more, with concentrates exceeding 80%, public health experts warn that higher potency may elevate risks, especially for young users, even as broader legalization increases access and normalization. In response, some states are proposing or implementing THC caps and stricter regulations, though disagreement persists among lawmakers, researchers and industry groups over how to balance consumer access with evolving evidence on health impacts. (CivicMedia)

💬 Idaho Moves to Block Voter‑Led Marijuana Legalization with Ballot Measure

Scientists discovered that removing a key enzyme (DAGLα) in the cerebellum disrupted the brain’s endocannabinoid system in mice, making them more anxious and less social. The enzyme normally produces 2-AG, a chemical messenger that helps neurons fine-tune their communication. Without it, the mice’s brain cells were less adaptable, affecting both movement and emotions. Researchers say the findings could lead to targeted therapies to boost endocannabinoid signaling and improve quality of life for people with autism, anxiety, and other social or emotional challenges.

👉 Read The Full Study Here

🪖 Review Finds Limited Evidence Supporting Medical Cannabis Use for PTSD

A comprehensive scoping review analyzing 26 studies and more than 3,500 patients found that high‑quality evidence supporting the effectiveness of medical cannabis for PTSD remains limited, with most randomized controlled trials showing little to no significant improvement over placebo. While some observational studies reported symptom relief in areas like sleep, nightmares and quality of life, these findings were often based on self‑reported data and carried a high risk of bias, reducing confidence in their conclusions. Overall, researchers concluded that although cannabis appears to be generally well tolerated with mostly mild side effects, stronger clinical trials are needed before it can be recommended as a reliable treatment for PTSD. (Business of Cannabis)

🗓️ Continued Cannabis News & Events

• Legislation to eliminate residency requirement for cannabis license applicants moving ahead

• Only on 19: Medical cannabis access facing more delays

• KY gov blasts GOP leader over medical cannabis prosecution comments: ‘Complete lack of humanity’ 

• Stoned rats get the munchies. Here's what that means for people with eating disorders, appetite loss